Related Experiment Video
Updated: Jun 5, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine
Fjoralba Kristo1, Sneha S Kelkar2, Rutika Raina2
1Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Insights
Real-world data show peripheral T-cell lymphoma (PTCL) patients in Europe receive varied first-line treatments. Outcomes include a median progression-free survival of 49.4 months and overall survival of 77.1 months, with significant cost variations by country.
Area of Science:
- Oncology
- Hematology
- Real-world evidence
Background:
- Limited real-world data on care patterns for peripheral T-cell lymphoma (PTCL) patients.
- Understanding treatment variations and outcomes in European PTCL patients is crucial.
Purpose of the Study:
- To report on care patterns and outcomes in first-line PTCL treatment across France, UK, Germany, and Italy.
- To analyze real-world data on treatments, response rates, survival, and costs.
Main Methods:
- Retrospective chart review of adult PTCL patients with newly diagnosed disease.
- Inclusion criteria: ≥1 line of therapy and ≥1 year of follow-up data.
- Outcomes assessed: treatments, best response, progression-free survival (PFS), overall survival (OS), and treatment costs.
Main Results:
- 195 patients analyzed from France (53), UK (56), Germany (56), and Italy (30).
- Common first-line regimens: CHOP (49.7%) and CHOEP (36.4%). Complete response rate was 59.7%.
- Median PFS: 49.4 months; median OS: 77.1 months. First-line treatment costs highest in the UK, driven by different factors per country.
Conclusions:
- This analysis enhances understanding of treatment outcomes and costs for PTCL patients in Europe.
- Real-world data reveal significant variations in care patterns and associated costs across European countries.
Purpose:
Limited real-world data exist on care patterns in peripheral T-cell lymphoma (PTCL) patients. We report care patterns and outcomes among PTCL patients in France, the United Kingdom (UK), Germany, and Italy in the first-line setting.
Patients And Methods:
A retrospective chart review was undertaken for adults with newly diagnosed PTCL. Eligible patients received ≥1 line of therapy (LOT) and had clinical data for ≥1 year after diagnosis or until death. Outcomes included treatments, best response at the end of 1LOT, progression-free survival (PFS) and overall survival (OS).
Results:
Data from 195 patients (France=53; UK=56; Germany=56; Italy=30) were collected. Median age at diagnosis was 62.0 years, with 73.3% at stage III/IV. The most common histological subtype was PTCL-not otherwise specified (36.9%). For 1LOT, 49.7% and 36.4% of patients received CHOP and CHOEP regimens, respectively. A complete response was reported in 59.7% of patients. Median PFS from 1LOT initiation was 49.4 months; median OS was 77.1 months. First-line treatment costs were highest in the UK. The cost drivers were adjunctive therapy in France and Germany; stem cell transplant and hospitalization in the UK and Italy, respectively.
Conclusion:
This analysis improves the understanding of treatment outcomes and costs in PTCL patients in Europe.
More Related Videos
07:39Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers